ProMIS Neurosciences shares are trading lower. The company presented preclinical data at the 2024 Alzheimer's Association International Conference.
Portfolio Pulse from Benzinga Newsdesk
ProMIS Neurosciences shares are trading lower after the company presented preclinical data at the 2024 Alzheimer's Association International Conference.
July 30, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ProMIS Neurosciences shares are trading lower after presenting preclinical data at the 2024 Alzheimer's Association International Conference.
The decline in ProMIS Neurosciences' share price suggests that investors were not impressed by the preclinical data presented at the conference. This could indicate concerns about the company's progress or the potential efficacy of its treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100